Roflumilast and dyspnea in patients with moderate to very severe chronic obstructive pulmonary disease

A pooled analysis of four clinical trials

Stephen Israel Rennard, Shawn X. Sun, Stavros Tourkodimitris, Paul Rowe, Udo M. Goehring, Dirk Bredenbröker, Peter M.A. Calverley

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Purpose: Breathlessness is a predominant symptom of chronic obstructive pulmonary disease (COPD), making it a valuable outcome in addition to lung function to assess treatment benefit. The phosphodiesterase-4 inhibitor roflumilast has been shown to provide small but significant improvements in dyspnea, as measured by the transition dyspnea index (TDI), in two 1-year studies in patients with severe to very severe COPD. Patients and methods: To provide a more comprehensive assessment of the impact of roflumilast on dyspnea, post hoc analyses of four 1-year roflumilast studies (M2-111, M2-112, M2-124, and M2-125) in patients with moderate to very severe COPD were conducted. Results: In this pooled analysis (N=5,595), roflumilast significantly improved TDI focal scores versus placebo at week 52 (treatment difference, 0.327; P<0.0001). Roflumilast was associated with significantly greater TDI responders and significantly fewer TDI deteriorators (≥1-unit increase or decrease from baseline, respectively) versus placebo at week 52 (P<0.01, both); these significant differences were apparent by week 8 and maintained until study end (P<0.05, all). At study end, the postbronchodilator forced expiratory volume in 1 second improvement in TDI responders was significantly greater with roflumilast versus placebo (P<0.05). Similar to the overall population, improvements in TDI focal scores at week 52 were small but consistently significant over placebo in patients with chronic bronchitis, regardless of exacerbation history, concomitant treatment with short-acting muscarinic antagonists or long-acting β2-agonists, or pretreatment with inhaled corticosteroids. Conclusion: This analysis shows that patients treated with roflumilast to reduce exacerbation risk may also experience small but significant improvements in dyspnea, with accompanying improvements in lung function.

Original languageEnglish (US)
Pages (from-to)657-673
Number of pages17
JournalInternational Journal of COPD
Volume9
DOIs
StatePublished - Jun 24 2014

Fingerprint

Dyspnea
Chronic Obstructive Pulmonary Disease
Clinical Trials
Placebos
Roflumilast
Phosphodiesterase 4 Inhibitors
Lung
Muscarinic Antagonists
Chronic Bronchitis
Forced Expiratory Volume
Adrenal Cortex Hormones
Therapeutics
History

Keywords

  • Breathlessness
  • Lung function
  • Phosphodiesterase-4 inhibitor
  • Subgroup analyses

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Health Policy
  • Public Health, Environmental and Occupational Health

Cite this

Rennard, S. I., Sun, S. X., Tourkodimitris, S., Rowe, P., Goehring, U. M., Bredenbröker, D., & Calverley, P. M. A. (2014). Roflumilast and dyspnea in patients with moderate to very severe chronic obstructive pulmonary disease: A pooled analysis of four clinical trials. International Journal of COPD, 9, 657-673. https://doi.org/10.2147/COPD.S55738

Roflumilast and dyspnea in patients with moderate to very severe chronic obstructive pulmonary disease : A pooled analysis of four clinical trials. / Rennard, Stephen Israel; Sun, Shawn X.; Tourkodimitris, Stavros; Rowe, Paul; Goehring, Udo M.; Bredenbröker, Dirk; Calverley, Peter M.A.

In: International Journal of COPD, Vol. 9, 24.06.2014, p. 657-673.

Research output: Contribution to journalArticle

Rennard, Stephen Israel ; Sun, Shawn X. ; Tourkodimitris, Stavros ; Rowe, Paul ; Goehring, Udo M. ; Bredenbröker, Dirk ; Calverley, Peter M.A. / Roflumilast and dyspnea in patients with moderate to very severe chronic obstructive pulmonary disease : A pooled analysis of four clinical trials. In: International Journal of COPD. 2014 ; Vol. 9. pp. 657-673.
@article{6ed17d2b089c4790a8ae3722c26e3bec,
title = "Roflumilast and dyspnea in patients with moderate to very severe chronic obstructive pulmonary disease: A pooled analysis of four clinical trials",
abstract = "Purpose: Breathlessness is a predominant symptom of chronic obstructive pulmonary disease (COPD), making it a valuable outcome in addition to lung function to assess treatment benefit. The phosphodiesterase-4 inhibitor roflumilast has been shown to provide small but significant improvements in dyspnea, as measured by the transition dyspnea index (TDI), in two 1-year studies in patients with severe to very severe COPD. Patients and methods: To provide a more comprehensive assessment of the impact of roflumilast on dyspnea, post hoc analyses of four 1-year roflumilast studies (M2-111, M2-112, M2-124, and M2-125) in patients with moderate to very severe COPD were conducted. Results: In this pooled analysis (N=5,595), roflumilast significantly improved TDI focal scores versus placebo at week 52 (treatment difference, 0.327; P<0.0001). Roflumilast was associated with significantly greater TDI responders and significantly fewer TDI deteriorators (≥1-unit increase or decrease from baseline, respectively) versus placebo at week 52 (P<0.01, both); these significant differences were apparent by week 8 and maintained until study end (P<0.05, all). At study end, the postbronchodilator forced expiratory volume in 1 second improvement in TDI responders was significantly greater with roflumilast versus placebo (P<0.05). Similar to the overall population, improvements in TDI focal scores at week 52 were small but consistently significant over placebo in patients with chronic bronchitis, regardless of exacerbation history, concomitant treatment with short-acting muscarinic antagonists or long-acting β2-agonists, or pretreatment with inhaled corticosteroids. Conclusion: This analysis shows that patients treated with roflumilast to reduce exacerbation risk may also experience small but significant improvements in dyspnea, with accompanying improvements in lung function.",
keywords = "Breathlessness, Lung function, Phosphodiesterase-4 inhibitor, Subgroup analyses",
author = "Rennard, {Stephen Israel} and Sun, {Shawn X.} and Stavros Tourkodimitris and Paul Rowe and Goehring, {Udo M.} and Dirk Bredenbr{\"o}ker and Calverley, {Peter M.A.}",
year = "2014",
month = "6",
day = "24",
doi = "10.2147/COPD.S55738",
language = "English (US)",
volume = "9",
pages = "657--673",
journal = "International Journal of COPD",
issn = "1176-9106",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Roflumilast and dyspnea in patients with moderate to very severe chronic obstructive pulmonary disease

T2 - A pooled analysis of four clinical trials

AU - Rennard, Stephen Israel

AU - Sun, Shawn X.

AU - Tourkodimitris, Stavros

AU - Rowe, Paul

AU - Goehring, Udo M.

AU - Bredenbröker, Dirk

AU - Calverley, Peter M.A.

PY - 2014/6/24

Y1 - 2014/6/24

N2 - Purpose: Breathlessness is a predominant symptom of chronic obstructive pulmonary disease (COPD), making it a valuable outcome in addition to lung function to assess treatment benefit. The phosphodiesterase-4 inhibitor roflumilast has been shown to provide small but significant improvements in dyspnea, as measured by the transition dyspnea index (TDI), in two 1-year studies in patients with severe to very severe COPD. Patients and methods: To provide a more comprehensive assessment of the impact of roflumilast on dyspnea, post hoc analyses of four 1-year roflumilast studies (M2-111, M2-112, M2-124, and M2-125) in patients with moderate to very severe COPD were conducted. Results: In this pooled analysis (N=5,595), roflumilast significantly improved TDI focal scores versus placebo at week 52 (treatment difference, 0.327; P<0.0001). Roflumilast was associated with significantly greater TDI responders and significantly fewer TDI deteriorators (≥1-unit increase or decrease from baseline, respectively) versus placebo at week 52 (P<0.01, both); these significant differences were apparent by week 8 and maintained until study end (P<0.05, all). At study end, the postbronchodilator forced expiratory volume in 1 second improvement in TDI responders was significantly greater with roflumilast versus placebo (P<0.05). Similar to the overall population, improvements in TDI focal scores at week 52 were small but consistently significant over placebo in patients with chronic bronchitis, regardless of exacerbation history, concomitant treatment with short-acting muscarinic antagonists or long-acting β2-agonists, or pretreatment with inhaled corticosteroids. Conclusion: This analysis shows that patients treated with roflumilast to reduce exacerbation risk may also experience small but significant improvements in dyspnea, with accompanying improvements in lung function.

AB - Purpose: Breathlessness is a predominant symptom of chronic obstructive pulmonary disease (COPD), making it a valuable outcome in addition to lung function to assess treatment benefit. The phosphodiesterase-4 inhibitor roflumilast has been shown to provide small but significant improvements in dyspnea, as measured by the transition dyspnea index (TDI), in two 1-year studies in patients with severe to very severe COPD. Patients and methods: To provide a more comprehensive assessment of the impact of roflumilast on dyspnea, post hoc analyses of four 1-year roflumilast studies (M2-111, M2-112, M2-124, and M2-125) in patients with moderate to very severe COPD were conducted. Results: In this pooled analysis (N=5,595), roflumilast significantly improved TDI focal scores versus placebo at week 52 (treatment difference, 0.327; P<0.0001). Roflumilast was associated with significantly greater TDI responders and significantly fewer TDI deteriorators (≥1-unit increase or decrease from baseline, respectively) versus placebo at week 52 (P<0.01, both); these significant differences were apparent by week 8 and maintained until study end (P<0.05, all). At study end, the postbronchodilator forced expiratory volume in 1 second improvement in TDI responders was significantly greater with roflumilast versus placebo (P<0.05). Similar to the overall population, improvements in TDI focal scores at week 52 were small but consistently significant over placebo in patients with chronic bronchitis, regardless of exacerbation history, concomitant treatment with short-acting muscarinic antagonists or long-acting β2-agonists, or pretreatment with inhaled corticosteroids. Conclusion: This analysis shows that patients treated with roflumilast to reduce exacerbation risk may also experience small but significant improvements in dyspnea, with accompanying improvements in lung function.

KW - Breathlessness

KW - Lung function

KW - Phosphodiesterase-4 inhibitor

KW - Subgroup analyses

UR - http://www.scopus.com/inward/record.url?scp=84903268704&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903268704&partnerID=8YFLogxK

U2 - 10.2147/COPD.S55738

DO - 10.2147/COPD.S55738

M3 - Article

VL - 9

SP - 657

EP - 673

JO - International Journal of COPD

JF - International Journal of COPD

SN - 1176-9106

ER -